Skip to content

Fatty Liver Disease (MASLD/NAFLD) Naturopathic Support in Toronto

picture of Mediterranean diet foods for fatty liver disease, NAFLD, or MASLD

Fatty liver disease used to get diagnosed almost by accident. A patient would come in for something else, bloodwork would show elevated ALT or AST, and an ultrasound ordered to chase down the cause would turn up steatosis (fatty liver) nobody expected. Partly because there would be no symptoms of this fat infiltrating the liver tissue. Metabolic dysfunction-associated steatotic liver disease, the term now replacing NAFLD (Non-Alcoholic Fatty Liver Disease) in the medical literature, affects roughly a quarter of adults worldwide, and most of them have no idea their liver is involved until a lab report tells them.

Contents show

I spent years running biochemistry and hematology panels in a hospital lab before I became a naturopathic doctor. That background shapes how I approach fatty liver: as a metabolic condition with measurable markers, not a vague issue or something that is insignificant. The liver sits at the center of insulin signalling, lipid (fat) handling, and detoxification, so when it’s under strain, the ripple effects show up in blood glucose, cholesterol, hormone metabolism, and energy levels long before symptoms do.

What MASLD Actually Is

MASLD describes fat accumulation in the liver in people who drink little or no alcohol, occurring alongside at least one cardiometabolic risk factor such as excess weight – particularly in the abdomen – elevated blood pressure, insulin resistance, or dyslipidemia. Simple steatosis, fat without much inflammation, sits at one end of the spectrum. Metabolic dysfunction-associated steatohepatitis (MASH, previously called NASH) sits further along, with inflammation and hepatocyte (liver cell) injury that can progress to fibrosis, cirrhosis, and in a minority of cases liver failure.

Most people with simple steatosis never progress to MASH. The problem is that nobody can tell, from symptoms alone, which category they’re in. Fatigue, mild right upper quadrant discomfort, or nothing at all can accompany either stage. That’s why testing matters more than how someone feels day to day.

Why Testing Comes First

I don’t treat fatty liver from a guess. A proper workup typically includes:

  • Liver enzymes (ALT, AST, GGT) and how they trend over time, not just a single value
  • Fasting insulin and glucose, and HbA1c, since insulin resistance drives most MASLD
  • A full lipid panel, including triglycerides, total cholesterol, LDL, non-HDL and HDL, which often move before the liver enzymes do
  • Ferritin, and a full iron panel, since iron overload patterns show up frequently alongside fatty liver
  • Thyroid function (TSH, free T4, free T3, anti-TPO, anti-thyroglobulin), because hypothyroidism is an under-recognized contributor to hepatic fat accumulation
  • Imaging through your MD (Ontario Naturopathic Doctors cannot order imaging), such as ultrasound, FibroScan (transient elastography), or MRI-PDFF where indicated, to assess fat content and fibrosis staging directly

Elevated liver enzymes are common enough that they get dismissed as “just a bit high,” but a GGT or ALT creeping upward over consecutive panels is data, not something to be ignored. Ontario patients can access basic liver enzyme testing through OHIP with a medical doctor’s requisition; more specialized markers or elastography sometimes require private lab access or referral from your MD to an internal medicine specialist.

The Fatty Liver Diet Evidence

Diet composition matters. A 2025 randomized controlled trial comparing a Mediterranean diet against a standard low-fat diet in 250 adults with MASLD found both approaches produced comparable improvements in liver fat and fibrosis markers at twelve weeks, regardless of PNPLA3 genetic variant.1 Neither diet beat the other. What mattered was adherence and caloric reduction.

That doesn’t mean diet quality is irrelevant. A meta-analysis of randomized trials found the Mediterranean diet, particularly when combined with aerobic exercise, produced meaningful reductions in body weight, BMI, and liver enzyme markers compared to standard care.2 Earlier trial data reported hepatic steatosis reductions as high as 39% over twelve weeks on a Mediterranean pattern, alongside improved insulin sensitivity. The mechanism likely runs through reduced refined carbohydrate and saturated fat intake, higher fibre and polyphenol content, and better omega-3 to omega-6 balance, all of which influence hepatic lipid handling independent of calories.

For patients, I translate this into something concrete: extra-virgin olive oil as the primary fat source, fatty fish two to three times weekly, a genuine reduction in processed food, carbs, and added sugar, and enough fibre from vegetables and legumes to support insulin sensitivity. Fructose from sugar-sweetened beverages deserves particular attention, since it drives fat production (lipogenesis) in the liver more directly than other sugars.

Weight Loss Thresholds That Matter for Fatty Liver

This is where the research gets specific enough to be genuinely useful. A prospective study following 293 patients with biopsy-confirmed steatohepatitis through a year of lifestyle intervention found a clear dose-response relationship.3 Patients losing 5% or more of body weight had meaningfully higher rates of steatohepatitis resolution than those losing less. Patients reaching 10% or more saw resolution in 90% of cases and fibrosis regression in 45%. A separate analysis of two large NASH trials found each kilogram lost was independently associated with a 7% increase in the odds of disease resolution.4

The takeaway for patients isn’t “lose as much weight as possible as fast as possible.” It’s that even modest, sustained loss (5%) produces measurable hepatic benefit, and the 7 to 10% range is where the cellular and tissue (histological) picture tends to shift substantially. That reframes weight loss goals away from aesthetics and toward a specific, evidence-anchored target tied to liver health.

Exercise, Independent of Weight Change

Exercise improves hepatic fat content even without significant weight loss, through improved insulin sensitivity and mitochondrial fatty acid oxidation in the liver itself. The same meta-analysis referenced above found aerobic exercise, alone or combined with resistance training, supported both weight reduction and liver-specific outcomes across the trials reviewed.2 For patients who find dietary change slower to implement, building in 150 minutes of moderate aerobic activity weekly, with resistance training added where tolerated, gives the liver a parallel lever to pull.

Coffee

This one surprises people. A systematic review pooling observational data across thousands of patients found regular coffee consumption associated with a 35% reduction in the odds of significant liver fibrosis among those with MASLD.5 The association didn’t hold for preventing MASLD in the first place, but among people who already have it, coffee drinkers showed meaningfully lower fibrosis risk. The mechanism is thought to involve chlorogenic acid and other polyphenols with antifibrotic and antioxidant activity in hepatic tissue. I don’t prescribe coffee as treatment, but for patients who already drink it and worry they should quit for liver reasons, the data doesn’t support that concern.

Where Supplementation for Fatty Liver Fits

Vitamin E

Vitamin E has the strongest trial evidence of any single nutrient for MASH specifically, with an important caveat. The PIVENS trial, a multicenter randomized controlled study, found 800 IU daily of RRR-alpha-tocopherol produced histologic improvement in 43% of non-diabetic, non-cirrhotic adults with biopsy-proven steatohepatitis, compared to 19% on placebo.6 That’s a meaningful effect size, but the trial population was narrow: no diabetes, no cirrhosis, and biopsy-confirmed aggressive disease. Vitamin E hasn’t shown the same benefit in diabetic patients or in simple steatosis without inflammation, and high-dose long-term use carries its own considerations that need individual risk assessment before starting.

Milk Thistle (Silymarin)

The evidence on silymarin is genuinely mixed, and I’d rather tell you that than oversell it. A 2024 meta-analysis pooling 26 randomized trials and over 2,300 patients found silymarin reduced ALT, AST, and several lipid markers, with improved hepatic steatosis on histology in the intervention group.7

An earlier, smaller meta-analysis reached similar conclusions on transaminase reduction.8 A broader systematic review spanning 29 trials and multiple liver conditions, not limited to MASLD, found roughly two-thirds of studies reported reduced liver enzymes with silymarin, while the remainder showed no change or, in a smaller subset, an increase, underscoring how much outcome depends on dose, formulation, and the underlying condition.9

My read: silymarin has a reasonable safety profile and plausible benefit for liver enzyme improvement, particularly at doses in the 140 to 700 mg range studied in trials, but it isn’t a substitute for the diet and weight interventions that carry stronger, more consistent evidence.

Choline

Emerging data on supplemental choline, particularly phosphatidylcholine forms, for hepatic fat metabolism looks promising but isn’t yet definitive enough to anchor a treatment plan on its own. It’s an area I’m watching and discuss with patients as an adjunct rather than a cornerstone.

What This Looks Like in Practice

A typical starting point involves baseline lab work to characterize where things stand, a structured conversation about caloric intake and Mediterranean-pattern food choices, a specific weight loss target framed around the 5 to 10% range where the research shows the biggest shift, an exercise plan matched to what a patient can actually sustain, and selective use of vitamin E or silymarin where the clinical picture supports it. Thorough lab work get addressed in parallel, since treating fatty liver in isolation while ignoring an underlying thyroid or insulin resistance issue tends to produce disappointing results.

Follow-up labs at intervals track whether the plan is working, rather than relying on how someone feels. That’s the lab tech in me. Fatty liver is a quiet condition. The numbers tell you what’s happening well before symptoms would.

Frequently Asked Questions About Fatty Liver Disease

Can fatty liver be reversed?

Simple steatosis and early-stage steatohepatitis both respond to sustained lifestyle change in the research reviewed above, particularly diet modification and weight loss in the 5 to 10% range. Advanced fibrosis or cirrhosis is a different clinical picture requiring hepatology involvement.

Do I need an ultrasound or can bloodwork alone diagnose fatty liver?

Elevated liver enzymes raise suspicion, but imaging or elastography gives a direct read on fat content and fibrosis staging. Bloodwork and imaging work together, not as substitutes for each other. Imaging needs to be ordered by your medical doctor.

Is intermittent fasting effective for fatty liver?

Time-restricted eating patterns can support caloric reduction and insulin sensitivity, both of which matter for hepatic fat, but the diet-composition trials above didn’t find any single dietary pattern outperforming others independent of overall caloric intake and adherence.

Can I take milk thistle without seeing a naturopathic doctor first?

Silymarin is generally well tolerated, but supplement quality varies widely, dosing in the trials ranged from 140 to 700 mg, and it can interact with certain medications metabolized through the same liver pathways. A proper intake before starting is worth the conversation.

Fatty Liver Disease References

  1. Dogay Us G, Innocenti F, Koc OM, Alagoz AE, Yumuk VD, Gungor ZB, Koek GH. Mediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial. Hepatol Commun. 2025 Nov 24;9(12):e0856. doi: 10.1097/HC9.0000000000000856. PMID: 41284948; PMCID: PMC12657048.
  2. Arita VA, Cabezas MC, Hernández Vargas JA, Trujillo-Cáceres SJ, Mendez Pernicone N, Bridge LA, Raeisi-Dehkordi H, Dietvorst CAW, Dekker R, Uriza-Pinzón JP, Tawfik M, Berk KA, Massoels J, Driessen S, Tushuizen ME, Holleboom AG, Grobbee DE, Franco OH, Beigrezaei S; GRIPonMASH Consortium. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2025 Aug 27;23(1):502. doi: 10.1186/s12916-025-04320-7. PMID: 40866968; PMCID: PMC12392582.
  3. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10. PMID: 25865049.
  4. Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2022 Mar;20(3):e538-e547. doi: 10.1016/j.cgh.2021.03.047. Epub 2021 Apr 2. PMID: 33813074.
  5. Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients. 2021 Aug 30;13(9):3042. doi: 10.3390/nu13093042. PMID: 34578919; PMCID: PMC8471033.
  6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. PMID: 20427778; PMCID: PMC2928471.
  7. Li S, Duan F, Li S, Lu B. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis. Ann Hepatol. 2024 Mar-Apr;29(2):101174. doi: 10.1016/j.aohep.2023.101174. Epub 2023 Oct 29. PMID: 38579127.
  8. Kalopitas G, Antza C, Doundoulakis I, Siargkas A, Kouroumalis E, Germanidis G, Samara M, Chourdakis M. Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Nutrition. 2021 Mar;83:111092. doi: 10.1016/j.nut.2020.111092. Epub 2020 Nov 25. PMID: 33418491.
  9. Calderon Martinez E, Herrera D, Mogan S, Hameed Z, Jangda AA, Khan TJ, Mroke P, Sajid S, Shah YR, Baig I. Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review. Cureus. 2023 Oct 24;15(10):e47608. doi: 10.7759/cureus.47608. PMID: 38021897; PMCID: PMC10667129.